Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass
Abstract
Checkpoint inhibitors are introduced as a therapy for clinical use for various cancers, and clinicians are documenting new adverse effects. This is the first case report to the best of our knowledge of a patient on checkpoint inhibitor presenting with both polyendocrinopathy and gangrenous gallbladder disease with a mass negative for malignancy.71-year-old man presented four years after his initial diagnosis of stage IV, unresectable,...
Paper Details
Title
Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass
Published Date
Jun 23, 2020
Journal
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History